ReviewArchives of microbiology2021
Therapeutic applications and biological activities of bacterial bioactive extracts.
Review in Archives of microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Mechanistic insights into HapC: A key enzyme in prodiginine biosynthesis in Hahella chejuensis.The FEBS journal · 2026Article
- Siwa spring microbiomes as reservoirs of biosynthetic gene clusters: Unlocking natural product potential.World journal of microbiology & biotechnology · 2026Article
- Anticancer Potential of Streptomyces sp. Strain M12: Apoptosis Induction and Anti-Migratory Effects in Colorectal Cancer Cells.Applied biochemistry and biotechnology · 2026Article
- Identification of Motilimonas thetidivivens sp. nov., a Novel Marine Gammaproteobacterium.Current microbiology · 2025Article
- Promising Prodiginins Biological Activities.Chemistry & biodiversity · 2025Review
- Characterization of Jannaschia halovivens sp. nov., Isolated from Seawater.Current microbiology · 2025Article
- From antibiotic to antiviral: computational screening reveals a multi-targeting antibiotic from Streptomyces spp. against Nipah virus fusion proteins.Molecular diversity · 2025Article
- Flagellimonas algarum sp. nov., isolated from dense mats of filamentous algae.Folia microbiologica · 2025Article
- Long-term sublingual bacterial immunotherapy prevents ear, nose and throat infections: A real-life study.SAGE open medicine · 2025Article
- Article
- Harnessing bacterial metabolites for enhanced cancer chemotherapy: unveiling unique therapeutic potentials.Archives of microbiology · 2024Review
- Antifungal, antiaflatoxigenic, and cytotoxic properties of bioactive secondary metabolites derived from Bacillus species.Scientific reports · 2024Article
- Silver nanoparticles synthesized fromBiofilm · 2024Article
- A comprehensive profiling of quorum quenching by bacterial pigments identifies quorum sensing inhibition and antibiofilm action of prodigiosin against Acinetobacter baumannii.Archives of microbiology · 2023Article
- Article
- Microbial Secondary Metabolites via Fermentation Approaches for Dietary Supplementation Formulations.Molecules (Basel, Switzerland) · 2023Review
- Returning to Nature for the Next Generation of Antimicrobial Therapeutics.Antibiotics (Basel, Switzerland) · 2023Review
- GC Analysis, Anticancer, and Antibacterial Activities of Secondary Bioactive Compounds from Endosymbiotic Bacteria of Pomegranate Aphid and Its Predator and Protector.Molecules (Basel, Switzerland) · 2023Article
- Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory.International journal of molecular sciences · 2023Review
- One Health Probiotics as Biocontrol Agents: One Health Tomato Probiotics.Plants (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria are rich in a wide variety of secondary metabolites, such as pigments, alkaloids, antibiotics, and others. These bioactive microbial products serve a great application in human and animal health. Their molecular diversity allows these natural products to possess several therapeutic attributes and biological functions. That's why the current natural drug industry focuses on uncovering all the possible ailments and diseases that could be combated by bacterial extracts and their secondary metabolites. In this paper, we review the major utilizations of bacterial natural products for the treatment of cancer, inflammatory diseases, allergies, autoimmune diseases, infections and other diseases that threaten public health. We also elaborate on the identified biological activities of bacterial secondary metabolites including antibacterial, antifungal, antiviral and antioxidant activities all of which are essential nowadays with the emergence of drug-resistant microbial pathogens. Throughout this review, we discuss the possible mechanisms of actions in which bacterial-derived biologically active molecular entities could possess healing properties to inspire the development of new therapeutic agents in academia and industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.